-
Symeres acquires Organix Inc., adding lipids expertise and a strategic foothold in the US
SYMERES PRESS RELEASE Nijmegen, The Netherlands – April 26, 2022: Symeres, […]
-
Is your drug development program lacking in vitro drug-drug interaction data?
We can support you with the safety evaluation required for investigational […]
-
In vivo metabolite identification and safety evaluation of human metabolites
To support understanding whether the drug metabolites can be considered safe, […]
-
New article on physiologically based pharmacokinetic modeling
Admescope’s top expert on physiologically based pharmacokinetic (PBPK) modeling, Dr Aki Heikkinen, […]
-
Admescope team welcomes a new CEO!
We are excited to announce Admescope team growing with an appointment of Dr […]
-
Do you need support with your Biologics project?
Admescope has been providing research services for biologics over few years now. We […]
-
New Admescope e-book is out!
Since Admescope’s previously published six e-books have been taken very well […]
-
Press Release: Symeres, a leading European CRO and CDMO, joins forces with Keensight Capital
We are pleased to let you know that Keensight Capital, one […]
-
An upcoming webinar via Symeres – In vivo pharmacokinetic experiments in preclinical drug development
Are you planning to initiate PK studies or just willing to […]
-
Admescope continues to be highly rated by the customers!
The whole Admescope team wishes to thank all our customers, who […]
-
Don’t neglect the metabolites!
Even though the focus of research in drug discovery & development […]
-
MIST webinar and new publication
Metabolites in safety testing (MIST) webinar Dr Johanna Haglund, Head of […]
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
![](https://admescope.com/wp-content/themes/symeres-2023/dist/img/contact-image-primary.png)